natgillin/translations-raw huggingface dataset:
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART).
Zabilježeni su slučajevi osteonekroze, posebno kod bolesnika s opće poznatim faktorima rizika, uznapredovalom HIV bolesti ili kod dugotrajnog uzimanja kombinirane antiretroviralne terapije (CART).
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
• Periodička izvješća o neškodljivosti lijeka (PSUR-evi) Zahtjevi za podnošenje PSUR-eva za ovaj lijek navedeni su na referentnom popisu datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu Europske agencije za lijekove.
− Joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement as some patients taking these medicines may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Ukočenost zglobova, tupi bolovi i probadanja (osobito u kuku, koljenu i ramenu) i teškoće u kretanju jer neki bolesnici koji uzimaju ove lijekove mogu razviti bolest kostiju koja se naziva osteonekroza (odumiranje tkiva kostiju zbog gubitka opskrbe krvlju).
Through Week 48, genotypic resistance testing results were available from 75 patients in the QD group and 75 patients in the BID group who had incomplete virologic response.
Nakon 48 tjedana rezultati testiranja genotipske rezistencije su dostupni od 75 bolesnika iz QD grupe i 75 bolesnika iz BID grupe koji su imali nepotpun virološki odgovor.
The adequate dosing may be achieved with the two available strengths of lopinavir/ritonavir tablets: 100/25 mg and 200/50 mg.*
Odgovarajuća doza može se postići s dvije dostupne jačine tableta lopinavira/ritonavira: 100/25 mg i 200/50 mg.*
− Lopinavir/ritonavir must not be taken once daily with efavirenz, nevirapine, carbamazepine, phenobarbital and phenytoin.
Lopinavir/ritonavir se ne smije uzimati jednom dnevno s efavirenzom, nevirapinom, karbamazepinom, fenobarbitalom i fenitoinom.
A series of blood samples were collected pre-dose and at intervals over the course of 12 hours in trimester 2 and trimester 3, at birth, and 4-6 weeks postpartum (in women who continued treatment postdelivery) for pharmacokinetic analysis of total and unbound levels of plasma lopinavir concentrations.
Sakupljena je serija uzoraka krvi prije početka liječenja te u vremenskim razmacima tijekom 12 sati u 2. tromjesečju i 3. tromjesečju, pri porodu, te od 4. - 6. tjedna nakon poroda (kod žena koje su nastavile liječenje nakon poroda) za farmakokinetičku analizu ukupne i nevezane koncentracije lopinavira u plazmi.
Pre-dose lopinavir concentrations decline with time during multiple dosing, stabilising after approximately 10 days to 2 weeks.
Pri višekratnom doziranju, koncentracije lopinavira prije davanja sljedeće doze se s vremenom smanjuju i stabiliziraju nakon otprilike 10 dana do 2 tjedna.
Within this panel, the following mutations in HIV protease were associated with reduced in vitro susceptibility to lopinavir: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V and L90M.
U tom rasponu virusnih izolata sljedeće su mutacije HIVproteaze bile povezane sa smanjenom osjetljivošću na lopinavir in vitro: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V i L90M.
Of these, isolates from 96 nelfinavir-treated patients and 51 lopinavir/ritonavir-treated patients could be amplified for resistance testing.
Od prethodno navedenih, izolati 96 bolesnika liječenih nelfinavirom i 51 liječenih lopinavirom/ritonavirom mogli su se pojačati za testiranje rezistencije.
The safety of lopinavir/ritonavir has been investigated in over 2600 patients in Phase II-IV clinical trials, of which over 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily.
Sigurnost primjene lopinavira/ritonavira je ispitana u kliničkim ispitivanjima faze II-IV na preko 2600 bolesnika, od kojih je preko 700 primilo dozu od 800/200 mg (6 kapsula ili 4 tablete) jednom dnevno.
Lopinavir binds to both alpha1-acid glycoprotein (AAG) and albumin however, it has a higher affinity for AAG.
Lopinavir se veže i na alfa-1-kiseli glikoprotein (AAG) i na albumin, no ima veći afinitet za AAG.
Based on the current data available, lopinavir/ritonavir should not be administered once daily in paediatric patients (see section 5.1).
Na temelju trenutno dostupnih podataka, lopinavir/ritonavir se ne smije dozirati jednom dnevno kod pedijatrijskih bolesnika (vidjeti dio 5.1).
Table 6 Mean (%CV) Steady-State Pharmacokinetic Parameters of Lopinavir in HIV-Infected Pregnant Women
Srednji (%CV) farmakokinetički parametar lopinavira u stanju dinamičke ravnoteže u trudnica s HIV infekcijom
Like all medicines, lopinavir/ritonavir can cause side effects, although not everybody gets them.
Kao i drugi lijekovi, lopinavir/ritonavir može izazvati nuspojave, iako se one neće javiti kod svakoga.
Effects on drug levels Geometric Mean Change (%) in AUC, Cmax, Cmin Mechanism of interaction
Geometrijska sredina promjene (%) u AUC, Cmax, Cmin
The frequency category includes all reported events of moderate to severe intensity, regardless of the individual causality assessment.
Kategorija učestalosti uključuje sve zabilježene događaje, po težini umjerene do teške, nevezano za individualnu procjenu povezanosti.
When co-administered with Lopinavir/Ritonavir Mylan, sildenafil doses must not exceed 25 mg in 48 hours and tadalafil doses must not exceed 10 mg every 72 hours.
Pri istodobnoj primjeni s lijekom Lopinavir/Ritonavir Mylan, doze sildenafila ne smiju biti veće od 25 mg u 48 sati, a doze tadalafila ne smiju biti veće od 10 mg svaka 72 sata.
For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions).
U bolesnika kod kojih je završena faza povećavanja doze i primaju stalnu dnevnu dozu venetoklaksa, smanjite dozu venetoklaksa najmanje 75% ako se upotrebljava zajedno sa snažnim inhibitorima CYP3A (upute o doziranju potražite u Sažetku opisa svojstava lijeka za venetoklaks).
Beta2-adrenoceptor agonist (long acting) Salmeterol
Agonisti Beta2-adrenoreceptora (dugodjelujući) Salmeterol
Hepatitis C virus direct acting antivirals
Antivirusni lijekovi s direktnim djelovanjem na hepatitis C
− Symptoms of dizziness, lightheadedness, fainting or sensation of abnormal heartbeats.
Simptome omaglice, ošamućenost, nesvjesticu ili osjećaj nepravilnih otkucaja srca.
In the QD group, 6/75 (8%) patients demonstrated new primary protease inhibitor mutations (codons 30, 32, 48, 50, 82, 84, 90), as did 12/77 (16%) patients in the BID group.
U QD grupi kod 6/75 (8%) bolesnika je zabilježene nove primarne mutacije inhibitora proteaze (kodoni 30, 32, 48, 50, 82, 84, 90) kao i kod 12/77 (16%) bolesnika iz BID grupe.
Mutations L33F, I50V and V32I combined with I47V/A were also observed.
Također su zamjećene mutacije L33F, I50V i V32I u kombinaciji s mutacijom I47V/A.
- Your doctor has prescribed lopinavir/ritonavir to help to control your Human Immunodeficiency Virus (HIV) infection.
Liječnik Vam je propisao lopinavir/ritonavir kako bi Vam pomogao u kontroli infekcije virusom humane imunodeficijencije (HIV; engl.
For infants and young children unable to swallow tablets, more suitable formulations containing lopinavir/ritonavir should be checked for their availability.
Za dojenčad i malu djecu koja ne mogu progutati tablete treba provjeriti dostupnost prikladnijih forumlacija koje sadrže lopinavir/ritonavir.
Patients with advanced HIV disease may be at risk of elevated triglycerides and pancreatitis.
U bolesnika s uznapredovalom HIV bolešću može se povećati rizik od povišene razine triglicerida i od pankreatitisa.
Undesirable effects in clinical studies and post-marketing in adult patients System organ class
Nuspojave uočene u kliničkim ispitivanjima i postmarketinškom praćenju u odraslih bolesnika Klasifikacija organskih sustava
Lopinavir/ritonavir does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).
Lopinavir/ritonavir pri klinički značajnim koncentracijama ne inhibira CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 ni CYP1A2 (vidjeti dio 4.3).
Paediatric populations
Pedijatrijska populacija
− Thirst, frequent urination, blurred vision or weight loss as this may indicate raised sugar levels in the blood.
Žeđ, učestalo mokrenje, zamućenje vida ili gubitak težine jer to može upućivati na povišene razine šećera u krvi.
Read the list of medicines above ‘Do not take Lopinavir/Ritonavir Mylan with any of the following medicines' for information on medicines that you must not take with lopinavir/ritonavir.
Pročitajte popis lijekova gore pod "Nemojte uzimati Lopinavir/Ritonavir Mylan ako istodobno uzimate neke od sljedećih lijekova" za informacije o lijekovima koje ne smijete uzimati dok uzimate lopinavir/ritonavir.
Based on known metabolic profiles, clinically significant interactions are not expected between Lopinavir/Ritonavir Mylan and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Na temelju saznanja o metaboličkim profilima, ne očekuju se klinički značajne interakcije između lijeka Lopinavir/Ritonavir Mylan i dapsona, trimetoprima/sulfametoksazola, azitromicina ili flukonazola.
It is therefore important that you remain under the supervision of your doctor while taking lopinavir/ritonavir.
Stoga je važno da budete pod nadzorom liječnika za vrijeme liječenja lopinavirom/ritonavirom.
Rifabutin, 150 mg QD Rifabutin (parent drug and active 25O-desacetyl metabolite):
Rifabutin, 150 mg QD Rifabutin (matični lijek i djelatni 25-O-dezacetilni metabolit):
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Iako se smatra da je etiologija ove bolesti multifaktorijalna (uključujući upotrebu kortikosteroida, korištenje alkohola, jaku imunosupresiju, viši indeks tjelesne mase) zabilježeni su slučajevi osteonekroze osobito u bolesnika koji imaju uznapredovalu HIV bolest i/ili su primali kombiniranu antiretrovirusnu terapiju (CART) kroz duži vremenski period.
The use of a once daily dosing should be limited to those adult patients having only very few protease inhibitor (PI) associated mutations (i.e. less than 3 PI mutations in line with clinical trial results, see section 5.1 for the full description of the population) and should take into account the risk of a lesser sustainability of the virologic suppression (see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to the recommended standard twice daily dosing.
Jednodnevni režim doziranja mora biti ograničen na one odrasle bolesnike koji imaju vrlo malo mutijacija povezanih s inhibitorom proteaze (IP) (t.j. manje od 3 mutacije IP u skladu s rezultatima kliničkog ispitivanja, vidjeti dio 5.1 za potpuni opis populacije) te te se mora voditi računa o riziku smanjene održivosti supresije virusa (vidjeti dio 5.1) i višim rizikom za dijareju (vidjeti dio 4.8) u usporedbi s preporučenim standardnim režimom davanja dva puta dnevno.
Antimycobacterials Bedaquiline (single dose)
Antimikobakterici Bedakilin (pojedinačna doza)
Talk to your doctor or pharmacist before taking Lopinavir/Ritonavir Mylan.
Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Lopinavir/Ritonavir Mylan.
The 4-oxo and 4hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
Epimerni par 4-okso- i 4-hidroksimetabolita glavni su metaboliti s antivirusnim djelovanjem, no njihov je udio u ukupno izmjerenoj radioaktivnosti u plazmi neznatan.
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance.
Kroz 360 tjedana liječenja genotipska analiza virusnih izolata, koja je uspješno provedena u 19 od 28 bolesnika kod kojih je potvrđen HIV RNA iznad 400 kopija/ml, je otkrila nepostojanje primarnih ili aktivnih mjesta mutacija u proteazi (amino kiseline na pozicijama 8, 30, 32, 46, 47, 48, 50, 82, 84 i 90) ili fenotipsku rezistenciju inhibitora proteaze.
The effects of lopinavir/ritonavir (in combination with other antiretroviral agents) on biological markers (plasma HIV RNA levels and CD4+ T-cell counts) have been investigated in controlled studies of lopinavir/ritonavir of 48 to 360 weeks duration.
Učinci lopinavira/ritonavira (u kombinaciji s ostalim antiretrovirusnim lijekovima) na biološke biljege (razinu HIV RNA u plazmi i broj CD4+ T stanica) ispitivani su u nadziranom ispitivanju lopinavira/ritonavira u trajanju od 48 do 360 tjedana.
Since these patients had not previously been exposed to either lopinavir/ritonavir or efavirenz, part of the response may be attributed to the antiviral activity of efavirenz, particularly in patients harbouring highly lopinavir resistant virus.
Budući da bolesnici dotad nisu primali ni lopinavir/ritonavir ni efavirenz, odgovor se djelomice može pripisati i protuvirusnoj aktivnosti efavirenza, osobito u bolesnika zaraženih virusom izrazito rezistentnim na lopinavir.
When given with Lopinavir/Ritonavir Mylan the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example MondayWednesday-Friday).
Kada se daje zajedno s lijekom Lopinavir/Ritonavir Mylan, preporučena doza rifabutina je 150 mg 3 puta tjedno u određene dane (npr. ponedjeljak-srijedapetak).
Do not take Lopinavir/Ritonavir Mylan if: - you are allergic to lopinavir, ritonavir or any of the other ingredients of this medicine (listed in section 6); - you have severe liver problems.
Nemojte uzimati Lopinavir/Ritonavir Mylan ako: ste alergični na lopinavir, ritonavir ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6) imate teške jetrene tegobe.
Carbamazepine and Phenobarbital
Karbamazepin i Fenobarbital
Patients were administered emtricitabine 200 mg once daily and tenofovir DF 300 mg once daily.
Bolesnicima su također davani emtricitabin 200 mg jednom dnevno i tenofovir DF 300 mg jednom dnevno.
Sixty-one patients completed the study (35 patients received the recommended 400/100 mg twice daily dose throughout the study).
61 bolesnik završio je studiju (35 bolesnika primalo je preporučenu dozu od 400/100 mg dva puta dnevno tijekom cijelog ispitivanja).
Nevirapine, 200 mg BID Lopinavir: AUC: ↓ 27%
Nevirapin, 200 mg BID Lopinavir: AUC: ↓ 27%
When used for osteo-articular infections, where the coadministration is unavoidable, close clinical monitoring for muscular adverse events is strongly recommended (see section 4.4).
Kada se koristi za osteoartikularne infekcije pri čemu je istodobna primjena neizbježna, snažno je preporučeno pomno kliničko praćenje štetnih događaja povezanih s mišićnim sustavom (vidjeti dio 4.4).
When you travel or need to stay in the hospital make sure you will have enough lopinavir/ritonavir to last until you can get a new supply.
Ukoliko putujete ili ostajete neko vrijeme u bolnici, uzmite dovoljnu količinu lopinavira/ritonavira koja će potrajati dok ne dobijete novu količinu lopinavira/ritonavira.
Inhibition of HIV protease prevents cleavage of the gag-pol polyprotein resulting in the production of immature, non-infectious virus.
Inhibicijom proteaze HIV-a sprječava se cijepanje poliproteina gag-pol, zbog čega se stvara nezreli, neinfektivni virus.
(see section 4.5); - riociguat is not recommended (see section 4.5); - vorapaxar is not recommended (see section 4.5); - fusidic acid in osteo-articular infections is not recommended (see section 4.5); - salmeterol is not recommended (see section 4.5); - rivaroxaban is not recommended (see section 4.5).
Kombinacija lopinavira/ritonavira s: - tadalafilom, indiciranim za liječenje plućne arterijske hipertenzije, se ne preporučuje (vidjeti dio 4.5); - riocigvatom se ne preporučuje (vidjeti dio 4.5); - vorapaksarom se ne preporučuje (vidjeti dio 4.5); - fusidatnom kiselinom kod osteoartikularne infekcije nije preporučljiva (vidjeti dio 4.5); - salmeterolom se ne preporučuje (vidjeti dio 4.5); - rivaroksabanom se ne preporučuje (vidjeti dio 4.5).
The 19 isolates demonstrated a 4.3-fold increase in IC50 compared to baseline isolates (from 6.2- to 43-fold, compared to wild-type virus).
Ukupno 19 izolata pokazalo je porast od 4,3 puta u IC50 u usporedbi s početnim izolatima (povećanje od 6,2 puta do 43 puta, u usporedbi s divljim tipom virusa).
The efficacy data favouring the twice-daily regimen are reinforced by a differential in pharmacokinetic parameters significantly favouring the twice-daily regimen (see section 5.2).
Podaci o učinkovitosti govore u prilog doziranju dvaput na dan kao i razlike u farmakokinetičkim parametrima koji značajno govore u prilog doziranju dvaput na dan (vidjeti dio 5.2).
Strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure which could potentially increase the risk of bedaquiline related adverse reactions.
Snažni inhibitori CYP3A4 poput inhibitora proteaza mogu povisiti izloženost bedakilinu što može potencijalno dovesti do povećanog rizika od nuspojava uzrokovanih bedakilinom.
If a patient is already taking St John's wort, stop St John's wort and if possible check viral levels.
Ako bolesnik već uzima gospinu travu, treba ju prestati uzimati i ako je moguće provjeriti razinu virusa.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and can occur many months after initiation of treatment (see section 4.4).
Zabilježena je pojava autoimunih poremećaja (kao što je Gravesova bolest i autoimuni hepatitis), međtim, zabilježeno vrijeme do pojave je vrlo varijabilno i može se pojaviti i mnogo mjeseci nakon početka liječenja (vidjeti dio 4.4).
Blood glucose disorders including diabetes mellitus, hypertriglyceridaemia, hypercholesterolemia, weight decreased, decreased appetite
Poremećaj glukoze u krvi, uključujući diabetes mellitus, hipertrigiliceridemiju, hiperkolesterolemiju, smanjenje tjelesne težine, smanjenje apetita
Phosphodiesterase (PDE5) inhibitors Avanafil (ritonavir 600 mg BID)
Inhibitori fosfodiesteraze 5 (PDE5) Avanafil (ritonavir 600 mg BID)
Lopinavir/ritonavir has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation.
Utvrđeno je da lopinavir/ritonavir in vivo inducira vlastiti metabolizam i povećava biotransformaciju nekih lijekova koji se metaboliziraju putem enzima citokroma P450 (uključujući CYP2C9 i CYP2C19) i putem glukuronidacije.
In general, rebound isolates either retained (if cross-resistant at baseline) or developed significant cross-resistance to indinavir, saquinavir and atazanavir.
Izolirani sojevi kod porasta broja virusa su, uglavnom, sadržavali (ako su bili križno rezistentni na početku) ili razvili značajnu križnu rezistenciju na indinavir, sakvinavir i atazanavir.
If the benefit is considered to outweigh the risk and Lopinavir/Ritonavir Mylan must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity.
Ukoliko se smatra da korist nadmašuje rizik i lijek Lopinavir/Ritonavir Mylan se mora koristiti, dozu ibrutiniba treba smanjiti na 140 mg i pomno pratiti bolesnika radi toksičnosti.
If you are taking lopinavir/ritonavir once a day
Ako uzimate lopinavir/ritonavir jedanput na dan
Increased creatine phosphokinase (CPK), myalgia, myositis, and rarely, rhabdomyolysis have been reported with protease inhibitors, particularly in combination with nucleoside reverse transcriptase inhibitors.
Povišenje kreatin fosfokinaze (CPK), mijalgija, miozitis i rijetko rabdomioliza zabilježeni su tijekom primjene inhibitora proteaze, pogotovo u kombinaciji s nukleozidnim inhibitorima reverzne transkriptaze.
The signs of toxicity observed in mice, rats or dogs included decreased activity, ataxia, emaciation, dehydration and tremors.
Znakovi otrovanja kod miševa, štakora ili pasa obuhvaćaju smanjenu aktivnost, ataksiju, ekstremno mršavljenje, dehidraciju i tremor.
In case of co-administration of Lopinavir/Ritonavir Mylan with contraceptives containing ethinyl oestradiol (whatever the contraceptive formulation e.g. oral or patch), additional methods of contraception must be used.
U slučaju istodobne primjene lijeka Lopinavir/Ritonavir Mylan s kontraceptivima koji sadrže etinilestradiol (bez obzira na formulaciju kontraceptiva npr. je li primjena peroralna ili u flasteru), moraju se koristiti dodatne metode kontracepcije.
Caution is warranted and therapeutic drug concentration monitoring is recommended when available.
Nužan je oprez, a preporučuje se i terapijsko praćenje lijekova, ukoliko je ono moguće.
Recommended number of 100/25 mg tablets twice-daily
Preporučen broj tableta 100/25 mg dva puta dnevno
If the use of atorvastatin is considered strictly necessary, the lowest possible dose of atorvastatin should be administered with careful safety monitoring.
Ako se utvrdi da je primjena atorvastatina nužna, mora se primjeniti najniža moguća doza uz pažljivo nadziranje primjene.
The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients (see sections 4.4 and 5.1).
Izbor lopinavira/ritonavira za liječenje osoba s HIV-1 infekcijom, koji su prethodno primali inhibitor proteaze, mora se zasnivati na provjeri individualne virusne rezistencije i povijesti liječenja bolesnika (vidjeti dijelove 4.4 and 5.1).
Hypersensitivity including urticaria and angioedema
Preosjetljivost uključujući urtikariju i angioedem
No subject experienced an increase in QTcF of ≥ 60 ms from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 ms.
Niti jedna osoba koja je sudjelovala u studiji nije imala povećanje QTcF ≥ 60 msec u odnosu na početnu vrijednost ili QTcF interval koji je prešao klinički značajan prag od 500 msec.
− The usual adult dose is 400 mg/100 mg twice a day i.e. every 12 hours, in combination with other antiHIV medicines.
Uobičajena doza za odrasle je 400 mg/100 mg dva puta dnevno, tj. svakih 12 sati u kombinaciji s drugim anti- HIV lijekovima.
− Breast-feeding mothers should not take lopinavir/ritonavir unless specifically directed by the doctor.
Dojilje ne smiju uzimati lopinavir/ritonavir, osim ako im to izričito ne kaže liječnik.
HDPE bottle: After first opening, use within 120 days.
Boca od polietilena visoke gustoće (HDPE): nakon prvog otvaranja iskoristiti u roku od 120 dana.
The in vitro antiviral EC50 of lopinavir is approximately 10-fold lower than that of ritonavir.
Antivirusna EC50 lopinavira oko 10 puta je manja od one ritonavira in vitro.
After 48 weeks of treatment with lopinavir/ritonavir, efavirenz and nucleoside reverse transcriptase inhibitors, plasma HIV RNA ≤ 400 copies/ml was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with < 10-fold, 10 to 40-fold, and > 40-fold reduced susceptibility to lopinavir at baseline, respectively.
Nakon 48 tjedana terapije lopinavirom/ritonavirom, efavirenzom i nukleozidnim inhibitorima reverzne transkriptaze, ≤ 400 kopija HIV RNA/ml plazme nađeno je, redom, u 93% (25/27), 73% (11/15), i 25% (2/8) bolesnika s < 10 puta manjom, 10-40 puta manjom, i > 40 puta manjom početnom osjetljivošću na lopinavir.